Ghisoni E, Casalone V, Giannone G, Mittica G, Tuninetti V, Valabrega G. Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience. World J Clin Oncol 2019; 10(12): 391-401 [PMID: 31890648 DOI: 10.5306/wjco.v10.i12.391]
Corresponding Author of This Article
Giorgio Valabrega, MD, Assistant Professor, Candiolo Cancer Institute FPO-IRCCS, Torino 10060 Italy. giorgio.valabrega@ircc.it
Research Domain of This Article
Oncology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Dec 24, 2019; 10(12): 391-401 Published online Dec 24, 2019. doi: 10.5306/wjco.v10.i12.391
Table 1 Clinical and nutritional characteristics of the sample at baseline
Characteristics
n = 22
Age (yr, mean value)
61
Weight (kg, mean value ± SD)
64 ± 14.2
BMI (mean value ± SD)
25 ± 5.2
Allergies, n (%)
Yes
15 (68.2)
No
7 (31.8)
Smoke, n (%)
Yes
5 (22.7)
No
17 (77.3)
Alcohol, n (%)
Yes
8 (36.4)
No
14 (63.6)
Type of gynecological cancer, n (%)
Cervical cancer
5 (22.7)
Endometrial cancer
2 (9.1)
Ovarian cancer
15 (68.2)
Chemotherapy treatment, n (%)
Carboplatin
2 (9.2)
Carboplatin - Bevacizumab
1 (4.5)
Carboplatin - Caelyx
3 (13.6)
Carboplatin - Gemcitabine
2 (9.2)
Carboplatin - Taxol
9 (40.9)
Carboplatin - Gemcitabine - Bevacizumab
1 (4.5)
Cisplatin
3 (13.6)
Cisplatin – Bevacizumab
1 (4.5)
Number of lines, n (%)
I
14 (63.6)
II
7 (31.8)
III
1 (4.6)
Nutritional requirements
BEE in kcal (Average value ± SD)
1262.5 ± 146.6
TEE in kcal (Average value ± SD)
1678.9 ± 177.1
Mediterranean diet adherence
MDSS (mean value ± SD)
12.5 ± 3.4
MDSS ≥ 13, n (%)
12 (54.5)
MDSS < 13
10 (45.5)
Table 2 Anthropometric and nutritional characteristics of the two groups at the baseline according to the Mediterranean diet adherence score
MDSS ≥ 13
MDSS < 13
Total
(n = 12)
(n = 10)
(n = 22)
Age (yr, mean value ± SD)
64.9 ± 11.6
56.4 ± 11.9
61 ± 12.2
Weight (kg, mean value ± SD)
61.3 ± 11.4
67.2 ± 17
64 ± 14.2
BMI (mean value ± SD)
24.5 ± 4.3
25.7 ± 6.3
25 ± 5.2
MDSS (mean value ± SD)
15.1 ± 2.1
9.5 ± 1.7
12.5 ± 3.4
Average daily intake
Proteins (g, mean value ± SD)
67.8 ± 15.6
83.5 ± 32
74.9 ± 25.1
Fats (g, mean value ± SD)
73.7 ± 21.9
91.6 ± 41.2
81.8 ± 32.6
Saturated fats (g, mean value ± SD)
25.8 ± 7.4
33.1 ± 19.9
29.1 ± 14.6
Carbohydrates (g, mean value ± SD)
227.5 ± 37.7
208.3 ± 80
218.8 ± 59.8
Sugars (g, mean value ± SD)
91 ± 15
85,9 ± 29
88,7 ± 22
Fibers (g, mean value ± SD)
22 ± 4.5
17.3 ± 6
19.9 ± 5.6
Energy intake (kcal, mean value ± SD)
1893.3 ± 376.3
2038.7 ± 724.8
1959.4 ± 552.1
Fluid intake (mL, mean value ± SD)
1320.8 ± 491.5
1365 ± 704
1340.9 ± 582.6
Coverage of the TEE (mean % ± SD)
115.8 ± 20.2
117.7 ± 41.6
116.7 ± 30.9
Coverage of the TEE > 100%, n (%)
10 (83.3)
5 (50)
15 (68.2)
Table 3 Nutritional-anthropometric features derived from the analysis of the second food frequency questionnaire
MDSS ≥ 13
MDSS < 13
Total
(n = 12)
( n = 10)
( n = 22)
Weight (kg, mean value ± SD)
61 ± 11.3
67.2 ± 17.3
63.8 ± 14.3
BMI (mean value ± SD)
24.4 ± 4.3
25.7 ± 6.3
25 ± 5.2
MDSS (mean value ± SD)
13.3 ± 0.8
8.9 ± 2.6
11.3 ± 2.9
Average daily intake
Proteins (g, mean value ± SD)
56.1 ± 15.5
70.6 ± 34.2
62.7 ± 26.1
Fats (g, mean value ± SD)
60.6 ± 17.8
83 ± 29
70.8 ± 25.6
Saturated fats (g, mean value ± SD)
21.3 ± 6.6
27.5 ± 12
24.1 ± 9.7
Carbohydrates (g, mean value ± SD)
212.5 ± 55.9
215 ± 95.6
213.6 ± 74.5
Sugars (g, mean value ± SD)
87.9 ± 20.6
99 ± 37.9
93 ± 29.5
Fibers (g, mean value ± SD)
18.3 ± 5.5
18.7 ± 8.3
18.5 ± 6.8
Energy intake (kcal, mean value ± SD)
1633.8 ± 406.8
1921.7 ± 687.7
1764.6 ± 557.5
Fluid intake (mL, mean value ± SD)
1400 ± 495.5
1388.9 ± 416.7
1394.7 ± 427.5
Coverage of the TEE (%, mean value ± SD)
100.2 ± 24.5
110.4 ± 36.4
104.8 ± 30.1
Coverage of the TEE > 100%, n (%)
7 (58.3)
5 (50)
12 (54.5)
Table 4 Gastrointestinal toxicities’ score after first chemotherapy cycle in the whole study population and in the two study’s groups according to the Mediterranean diet serving score
MDSS ≥ 13
MDSS < 13
Total
P value
Dry mouth (G)
1 ± 1.3
1.1 ± 1.3
1 ± 1.3
0.85
Dysphagia (G)
0.3 ± 0.5
0.4 ± 0.7
0.3 ± 0.6
0.70
Oral sores (A)
0.2 ± 0.4
0.5 ± 1.3
0.3 ± 0.9
0.45
Oral sores (G)
0.1 ± 0.3
0.4 ± 1.3
0.2 ± 0.9
0.44
Mouth’s cracks (G)
0.1 ± 0.3
0.4 ± 1.3
0.2 ± 0.9
0.44
Dysgeusia (G)
0.9 ± 1.2
1 ± 1.2
1 ± 1.2
0.84
Loss of appetite (I.A)
1.1 ± 1.1
1.4 ± 1.5
1.2 ± 1.3
0.59
Loss of appetite (G)
1 ± 1
1.3 ± 1.7
1.1 ± 1.3
0.61
Nausea (F)
1.5 ± 1.1
1.4 ± 1.6
1.5 ± 1.3
0.86
Nausea (G)
1 ± 0.9
1.5 ± 1.7
1.2 ±1.3
0.38
Vomiting (F)
0.6 ± 0.8
0.6 ± 1.3
0.6 ± 1
1
Vomiting (G)
0.3 ± 0.5
0.6 ± 1.3
0.5 ± 1
0.46
Stomachache (F)
0.2 ± 0.6
0.7 ± 0.9
0.4 ± 0.8
0.13
Stomachache (G)
0.1 ± 0.3
0.5 ± 0.7
0.3 ± 0.6
0.08
Intestinal gas (yes/no)
0.4 ± 0.5
0.3 ± 0.5
0.4 ± 0.5
0.64
Bloating (F)
0.7 ± 0.9
0.5 ± 1
0.6 ± 0.9
0.62
Bloating (G)
0.3 ± 0.5
0.4 ± 0.7
0.4 ± 0.6
0.70
Constipation (G)
0.5 ± 0.5
0.7 ± 0.7
0.6 ± 0.6
0.44
Diarrhea (F)
0.7 ± 0.9
0.7 ± 1.3
0.7 ± 1.1
1
Abdomen ache (F)
1.1 ± 1
0.3 ± 0.7
0.7 ± 0.9
0.04
Abdomen ache (G)
0.8 ± 0.8
0.2 ± 0.4
0.5 ± 0.7
0.04
Abdomen ache (I.A)
0.7 ± 0.8
0.2 ± 0.6
0.5 ± 0.7
0.11
Toxicity (TOT)
13.4 ± 6.6
15.1 ± 14.5
14.2 ± 10.7
0.7
Table 5 Gastrointestinal toxicities’ score after last chemotherapy cycle in the whole study population and in the two study’s groups according to the Mediterranean diet serving score
MDSS ≥ 13
MDSS < 13
Total
P value
Dry mouth (G)
1.5 ± 1.8
0.8 ± 1.8
1.2 ± 1.7
0.53
Dysphagia (G)
0 ± 0
0.2 ± 0.4
0.1 ± 0.3
0.24
Oral sores (G)
0 ± 0
0 ± 0
0 ± 0
1
Oral sores (A)
0 ± 0
0 ± 0
0 ± 0
1
Mouth’s cracks (G)
0 ± 0
0.2 ± 0.4
0.1 ± 0.3
0.24
Dysgeusia (G)
1.3 ± 1.5
2.6 ± 1.9
1.9 ± 1.8
0.23
Loss of appetite (G)
1.3 ± 1.5
2.4 ± 1.7
1.8 ± 1.6
0.28
Loss of appetite (I.A)
1.3 ± 1.5
2 ± 1.4
1.6 ± 1.4
0.44
Nausea (F)
0.7 ± 1.6
3.6 ± 0.9
2 ± 2
< 0.01
Nausea (G)
0.7 ± 1.6
3.4 ± 0.9
1.9 ± 1.9
< 0.01
Vomiting (F)
0.3 ± 0.8
0.8 ± 1.3
0.5 ± 1
0.45
Vomiting (G)
0.2 ± 0.4
1 ± 1.7
0.5 ± 1.2
0.28
Stomach ache (F)
0 ± 0
1 ± 1
0.5 ± 0.8
0.03
Stomach ache (G)
0 ± 0
1.2 ± 1.3
0.5 ± 1
0.04
Gas (yes/no)
0.3 ± 0.5
0.4 ± 0.5
0.4 ± 0.5
0.74
Bloating (F)
0 ± 0
1.4 ± 1.3
0.6 ± 1.1
0.02
Bloating (G)
0 ± 0
1 ± 1
0.5 ± 0.8
0.03
Constipation (G)
0.8 ± 0.4
2.4 ± 1.8
1.5 ± 1.4
0.06
Diarrhea (F)
0.5 ± 0.8
1.2 ± 1.1
0.8 ± 1
0.25
Abdomen ache (F)
0.2 ± 0.4
1.4 ± 0.9
0.7 ± 0.9
0.01
Abdomen ache (G)
0.2 ± 0.4
1.2 ± 0.8
0.6 ± 0.8
0.02
Abdomen ache (I.A)
0.2 ± 0.4
1.2 ± 0.8
0.6 ± 0.8
0.02
GI toxicity (TOT)
9.5 ± 10.9
29.4 ± 10.4
18.5 ± 14.5
0.01
Citation: Ghisoni E, Casalone V, Giannone G, Mittica G, Tuninetti V, Valabrega G. Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience. World J Clin Oncol 2019; 10(12): 391-401